Last reviewed 2026-05-15 · How we verify

Clindamycin palmitate hydrochloride dispersible tablet

Guangzhou Yipinhong Pharmaceutical CO.,LTD · FDA-approved active Small molecule Quality 0/100

Clindamycin palmitate hydrochloride dispersible tablet is a Small molecule drug developed by Guangzhou Yipinhong Pharmaceutical CO.,LTD. It is currently FDA-approved. Also known as: No other Names.

Clindamycin palmitate hydrochloride dispersible tablet, marketed by Guangzhou Yipinhong Pharmaceutical CO., LTD, is an established antibiotic in the pharmaceutical market. The drug's key composition patent is set to expire in 2028, providing a significant period of market exclusivity. However, the lack of reported revenue and key trial results poses a primary risk, as it may affect investor confidence and market perception.

At a glance

Generic name	Clindamycin palmitate hydrochloride dispersible tablet
Also known as	No other Names
Sponsor	Guangzhou Yipinhong Pharmaceutical CO.,LTD
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clindamycin palmitate hydrochloride dispersible tablet CI brief — competitive landscape report
Clindamycin palmitate hydrochloride dispersible tablet updates RSS · CI watch RSS
Guangzhou Yipinhong Pharmaceutical CO.,LTD portfolio CI

Frequently asked questions about Clindamycin palmitate hydrochloride dispersible tablet

What is Clindamycin palmitate hydrochloride dispersible tablet?

Clindamycin palmitate hydrochloride dispersible tablet is a Small molecule drug developed by Guangzhou Yipinhong Pharmaceutical CO.,LTD.

Who makes Clindamycin palmitate hydrochloride dispersible tablet?

Clindamycin palmitate hydrochloride dispersible tablet is developed and marketed by Guangzhou Yipinhong Pharmaceutical CO.,LTD (see full Guangzhou Yipinhong Pharmaceutical CO.,LTD pipeline at /company/guangzhou-yipinhong-pharmaceutical-co-ltd).

Is Clindamycin palmitate hydrochloride dispersible tablet also known as anything else?

Clindamycin palmitate hydrochloride dispersible tablet is also known as No other Names.

What development phase is Clindamycin palmitate hydrochloride dispersible tablet in?

Clindamycin palmitate hydrochloride dispersible tablet is FDA-approved (marketed).

Manufacturer: Guangzhou Yipinhong Pharmaceutical CO.,LTD — full pipeline
Also known as: No other Names
Compare: Clindamycin palmitate hydrochloride dispersible tablet vs similar drugs
Pricing: Clindamycin palmitate hydrochloride dispersible tablet cost, discount & access